Development and evolution of human glutaminyl cyclase inhibitors (QCIs): an alternative promising approach for disease-modifying treatment of Alzheimer's disease

Development and evolution of human glutaminyl cyclase inhibitors (QCIs): an alternative promising approach for disease-modifying treatment of Alzheimer's disease

Human glutaminyl cyclase (hQC) is drawing considerable attention and emerging as a potential druggable target for Alzheimer's disease (AD) due to its close involvement in the pathology of AD via the post-translational pyroglutamate modification of amyloid-β. A recent phase 2a study has shown pr...

Full description

Bibliographic Details
Main Authors: Daoyuan Chen, Qingxiu Chen, Xiaofei Qin, Peipei Tong, Liping Peng, Tao Zhang, Chunli Xia
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-08-01
Series:Frontiers in Aging Neuroscience
Subjects:
Alzheimer's disease
human glutaminyl cyclase
amyloid-β
pyroglutamate modification
QC inhibitor
PQ912
Online Access:https://www.frontiersin.org/articles/10.3389/fnagi.2023.1209863/full

Internet

https://www.frontiersin.org/articles/10.3389/fnagi.2023.1209863/full

Similar Items